Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading ->
World Health Organization Director-General Dr Tedros Adhanom Ghebreyesus told reporters today that WHO is “working to find a balance between protecting patients and staff from attacks by armed groups and building community trust and ownership” in managing the response to the deadly Ebola epidemic in the Democratic Republic of Congo. Image Credits: Gabriele François Casini/MSF. Continue reading ->
The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading ->
Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading ->
Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading ->
The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading ->